

Juliana Alvares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2495237/publications.pdf>

Version: 2024-02-01

105
papers

1,292
citations

394421

19
h-index

501196

28
g-index

115
all docs

115
docs citations

115
times ranked

1676
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. <i>Aids</i> , 2005, 19, S5-S13.	2.2	81
2	Quality of life of patients in renal replacement therapy in Brazil: comparison of treatment modalities. <i>Quality of Life Research</i> , 2012, 21, 983-991.	3.1	48
3	Main characteristics of patients of primary health care services in Brazil. <i>Revista De Saude Publica</i> , 2017, 51, 17s.	1.7	44
4	Availability of essential medicines in primary health care of the Brazilian Unified Health System. <i>Revista De Saude Publica</i> , 2017, 51, 10s.	1.7	44
5	Polypharmacy:. <i>Revista De Saude Publica</i> , 2017, 51, 19s.	1.7	43
6	National Survey on Access, Use and Promotion of Rational Use of Medicines: methods. <i>Revista De Saude Publica</i> , 2017, 51, 4s.	1.7	37
7	Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications. <i>Patient</i> , 2018, 11, 377-389.	2.7	37
8	Pharmaceutical care in Brazilâ€™s primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 6s.	1.7	33
9	HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 279-287.	0.5	32
10	Budget impact analysis of medicines: updated systematic review and implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 257-266.	1.4	31
11	Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, DengvaxiaÂ®) in Brazil; Implications for Future Pricing Considerations. <i>Frontiers in Pharmacology</i> , 2017, 8, 41.	3.5	31
12	Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referral health centre in Minas Gerais, Brazil. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 739-746.	3.1	30
13	Indicators related to the rational use of medicines and its associated factors. <i>Revista De Saude Publica</i> , 2017, 51, 23s.	1.7	30
14	Access to medicines by patients of the primary health care in the Brazilian Unified Health System. <i>Revista De Saude Publica</i> , 2017, 51, 20s.	1.7	25
15	Integrative Review of Managed Entry Agreements: Chances and Limitations. <i>Pharmacoeconomics</i> , 2020, 38, 1165-1185.	3.3	25
16	Infrastructure of pharmacies of the primary health care in the Brazilian Unified Health System:. <i>Revista De Saude Publica</i> , 2017, 51, 13s.	1.7	23
17	Medicine dispensing service in primary health care of SUS. <i>Revista De Saude Publica</i> , 2017, 51, 11s.	1.7	23
18	Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2016, 7, 241-258.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Statin use in Brazil: findings and implications. <i>Current Medical Research and Opinion</i> , 2018, 34, 1809-1817.	1.9	21
20	Health-related quality of life of patients of Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 22s.	1.7	20
21	Management of pharmaceutical services in the Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 15s.	1.7	20
22	Technical issues and conservation conditions of medicines in the primary health care of the Brazilian Unified Health System. <i>Revista De Saude Publica</i> , 2017, 51, 12s.	1.7	20
23	Patient satisfaction with pharmaceutical services in Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 21s.	1.7	19
24	The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. <i>PLoS ONE</i> , 2018, 13, e0199446.	2.5	19
25	Use of medicines by patients of the primary health care of the Brazilian Unified Health System. <i>Revista De Saude Publica</i> , 2017, 51, 18s.	1.7	18
26	The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil. <i>Pharmacoeconomics</i> , 2018, 36, 161-173.	3.3	17
27	Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2349-2361.	2.4	16
28	Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 991-999.	3.1	15
29	Implementation of clinical guidelines in Brazil: should academic detailing be used?. <i>Journal of Pharmaceutical Health Services Research</i> , 2016, 7, 105-115.	0.6	14
30	Pharmaceutical services in the primary health care of the Brazilian Unified Health System:. <i>Revista De Saude Publica</i> , 2017, 51, 3s.	1.7	14
31	Workforce in the pharmaceutical services of the primary health care of SUS, Brazil. <i>Revista De Saude Publica</i> , 2017, 51, 16s.	1.7	14
32	Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 879-887.	3.0	14
33	Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 539-549.	1.4	13
34	Access to medicines:. <i>Revista De Saude Publica</i> , 2017, 51, 8s.	1.7	13
35	Medication persistence for psoriatic arthritis in a Brazilian real-world setting. <i>Future Science OA</i> , 2019, 5, FSO369.	1.9	13
36	The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 519-527.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Conceptions on pharmaceutical services in Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 5s.	1.7	12
38	Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 241-254.	3.2	12
39	Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 119-129.	1.4	12
40	Indicator of access to medicines in relation to the multiple dimensions of access. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1027-1041.	1.4	12
41	Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (Sistema Único de Saúde). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 403-412.	1.4	11
42	Financing of Pharmaceutical Services in the municipal management of the Brazilian Unified Health System. <i>Revista De Saude Publica</i> , 2017, 51, 14s.	1.7	11
43	Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. <i>Advances in Rheumatology</i> , 2019, 59, 48.	1.7	11
44	Pharmaceutical services in primary health care: interfederative agreement in the development of pharmaceutical policies in the Brazilian Unified Health System (SUS). <i>Revista De Saude Publica</i> , 2017, 51, 2s.	1.7	10
45	Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 989-1000.	1.4	10
46	Who should pay for the continuity of post-trial health care treatments?. <i>International Journal for Equity in Health</i> , 2019, 18, 26.	3.5	10
47	First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 363-370.	3.1	9
48	Confidentiality agreements: a challenge in market regulation. <i>International Journal for Equity in Health</i> , 2019, 18, 11.	3.5	8
49	Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications. <i>Value in Health Regional Issues</i> , 2021, 26, 135-141.	1.2	8
50	Saúde mental em estudantes universitários durante a pandemia de COVID-19. <i>Revista Família, Ciclos De Vida E Saúde No Contexto Social</i> , 2021, 9, 372.	0.1	7
51	Characterization of the selection of medicines for the Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 9s.	1.7	6
52	Characterization of the institutionalization of pharmaceutical services in Brazilian primary health care. <i>Revista De Saude Publica</i> , 2017, 51, 7s.	1.7	6
53	Uso de medicamentos por adultos na atenção primária: inquérito em serviços de saúde de Minas Gerais, Brasil. <i>Revista Brasileira De Epidemiologia</i> , 2020, 23, e200025.	0.8	6
54	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Oncology and Therapy</i> , 2021, 9, 505-524.	2.6	6

#	ARTICLE	IF	CITATIONS
55	Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. <i>Pharmacy Practice</i> , 2021, 19, 2312.	1.5	5
56	Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2015, 51, 709-719.	1.2	4
57	Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 21, 1-6.	1.4	4
58	Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study. <i>PLoS ONE</i> , 2020, 15, e0238476.	2.5	4
59	Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 473-479.	1.4	4
60	Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 243-253.	1.4	4
61	Influence of pharmaceutical services organization on the availability of essential medicines in a public health system. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 519-532.	1.4	4
62	Academic detailing program for rheumatoid arthritis: a contribution to Brazilian public health system sustainability. <i>Journal of Pharmaceutical Health Services Research</i> , 2020, 11, 249-254.	0.6	3
63	A cross-sectional study of the quality of life of patients living with type 1 diabetes treated with insulin glargine and neutral protamine Hagedorn insulin and the implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 332-342.	0.6	3
64	Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 509-517.	1.4	3
65	Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, , 1-11.	1.4	3
66	Access to medicines in the Brazilian Unified Health System's primary health care: assessment of a public policy. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 869-879.	1.4	3
67	Validity of the Frequency of Suicidal Ideation Inventory in Brazilian adults. <i>Death Studies</i> , 2020, , 1-5.	2.7	2
68	FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1217-1225.	3.0	2
69	Dezesseis Anos de Transplante Cardíaco em Coorte Aberta no Brasil: Análise de Sobrevida de Pacientes em Uso de Imunossupressores. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 744-753.	0.8	2
70	Cost-minimization analysis of teledermatology versus conventional care in the Brazilian National Health System. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1159-1168.	1.4	2
71	Social and economic factors associated with antidepressant use: Results of a national survey in primary care. <i>Journal of Affective Disorders Reports</i> , 2022, 8, 100307.	1.7	2
72	Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil. <i>Frontiers in Pharmacology</i> , 2022, 13, 878972.	3.5	2

#	ARTICLE	IF	CITATIONS
73	Análise De Impacto Orçamentário: Quanto Custaria Ao Sistema Público De Saúde Brasileiro Incrementar, Por Meio De Transplantes, O Tratamento Da Doença Renal Crônica Terminal?. Value in Health, 2013, 16, A665.	0.3	1
74	Efficacy And Safety of Antidiabetic Drugs Available on Brazilian Public Health System (Sus) – Regular Insulin, Nph Insulin, Metformin, Glibenclamide And Gliclazide – In Treatment of Type 2 Diabetes (T2dm) - Systematic Review And Meta-Analysis. Value in Health, 2015, 18, A862.	0.3	1
75	Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil. Expert Review of Clinical Pharmacology, 2020, 13, 1401-1409.	3.1	1
76	Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes. Hematology, Transfusion and Cell Therapy, 2021, , .	0.2	1
77	A longitudinal model for psychological distress in the COVID-19 crisis among brazilian graduate students. Psico, 2021, 52, e41332.	0.2	1
78	Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies. Frontiers in Pharmacology, 2020, 11, 572043.	3.5	1
79	There Is Evidence of Increased Risk of Cancer In Patients Using Human Insulin Analogue Glargine For Treatment of Diabetes Mellitus - Overview Based Evaluation. Value in Health, 2015, 18, A863.	0.3	0
80	Access To Medicines: Developing An Indicator To Assess The Impact of Public Policies. Value in Health, 2017, 20, A898.	0.3	0
81	VP49 Brazilian Consumer Willingness To Pay For Dengue Vaccine (CYD-TDV). International Journal of Technology Assessment in Health Care, 2017, 33, 170-171.	0.5	0
82	VP53 Cost-Utility Analysis: Adalimumab Versus Etanercept in Rheumatoid Arthritis – Brazil. International Journal of Technology Assessment in Health Care, 2017, 33, 171-172.	0.5	0
83	OP129 Predictors Of Effectiveness In Patients With Rheumatoid Arthritis. International Journal of Technology Assessment in Health Care, 2017, 33, 59-60.	0.5	0
84	PP44 Effectiveness Of Insulin Glargine Versus Detemir In Type 1 Diabetes. International Journal of Technology Assessment in Health Care, 2018, 34, 82-83.	0.5	0
85	PP114 Clinical Effectiveness Of Insulin Glargine; Findings And Implications. International Journal of Technology Assessment in Health Care, 2018, 34, 109-109.	0.5	0
86	PP118 Cardiac Safety Of Trastuzumab For Metastatic Breast Cancer. International Journal of Technology Assessment in Health Care, 2018, 34, 111-111.	0.5	0
87	PP76 Providing Information About Rheumatoid Arthritis Guideline In Brazil. International Journal of Technology Assessment in Health Care, 2018, 34, 96-97.	0.5	0
88	Crohn's Disease Treatment Expenditures over Fifteen Years of Follow-Up. Pharmacoeconomics Open Access, 2018, 03, .	0.1	0
89	PP142 Is Insulin Therapy Important For The Quality Of Life Of Diabetics?. International Journal of Technology Assessment in Health Care, 2018, 34, 122-122.	0.5	0
90	Profile of patients with head and neck cancer and evaluation of the quality of medical records in a public hospital. Revista Médica De Minas Gerais, 2018, 28, .	0.0	0

#	ARTICLE	IF	CITATIONS
91	Media Doctor Brasil: avaliação da qualidade de notícias em saúde. , 0, , .		0
92	Zolgensma e Atrofia Muscular Espinhal: evidências, incertezas e impacto orçamentário. , 0, , .		0
93	ANÁLISE DE EFETIVIDADE E SEGURANÇA DOS AGENTES ANTI - FATOR DE NECROSE TUMORAL PARA O TRATAMENTO DA ESPONDILITE ANQUILOSANTE NO SISTEMA NERVOSO DE SAÚDE: o SUS É para todos?. , 0, , .		0
94	PERSISTÊNCIA NO TRATAMENTO COM MEDICAMENTOS BIOLÓGICOS PARA ARTRITE PSORÍACA. , 0, , .		0
95	Burosumabe para tratamento de pacientes com raquitismo hipofosfático. , 0, , .		0
96	Voretigene neparvovec: a nova terapia gênica para doenças oculares. , 0, , .		0
97	MEIAS COMPRESSIVAS NA PREVENÇÃO DE ÚLCERAS VENOSAS. , 0, , .		0
98	PCDT da HPN: experiência na elaboração de um protocolo rápido. , 0, , .		0
99	REGIME TERAPÊUTICO E QUALIDADE DE VIDA DE PACIENTES HIPERTENSOS. Revista De Atenção À Saúde, 2019, 16, .	0.1	0
100	Impactos do avanço da pandemia de COVID-19 na saúde mental de profissionais de saúde. Psico, 2021, 52, e41302.	0.2	0
101	PP406 Academic Detailing For Judges: Concepts Of Evidence-Based Medicine And Health Policies Adopted In Brazil. International Journal of Technology Assessment in Health Care, 2020, 36, 34-35.	0.5	0
102	A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications. Clinical Diabetes, 0, , .	2.2	0
103	Survival Analysis of COPD Patients in a 13-Year Nationwide Cohort Study of the Brazilian National Health System. Frontiers in Big Data, 2021, 4, 788268.	2.9	0
104	Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6453.	0.7	0
105	Biological therapy in psoriatic arthritis patients with and without previous biologic experience. Medicina, 2022, 55, .	0.1	0